Pharmaceuticals

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

Pharma giant Bayer partners with biotech innovator Soufflé to develop a groundbreaking siRNA therapy, aiming to deliver genetic medicine directly to the heart.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Biotech leader Arrowhead Pharmaceuticals prices upsized offerings, signaling strong investor confidence and fueling its next wave of RNAi therapies.

The pharmaceutical giant is expanding its partnership with Veeva, adopting a next-gen CRM with agentic AI to transform its global commercial execution.

Dexcel Pharma USA acquires Zubsolv®, a key opioid addiction therapy, signaling a major strategic shift into the branded drug market in the U.S.

Acertis Pharmaceuticals secures rights to Licart, a unique once-daily NSAID patch, aiming to disrupt the competitive U.S. topical pain relief market.

From AI-powered diagnostics to non-hallucinogenic psychedelics, 2025's discoveries are redefining mental healthcare and offering new hope.

A biotech firm's promising concussion therapy, backed by NFL's Alex Smith, shows an 85% responder rate and now seeks public funding for its final push.

The deal merges digital orchestration with field AI, promising pharma a unified, rapid-deployment engagement solution to challenge industry giants.

Pharma giant Lilly and AI biotech BigHat are teaming up to solve a critical flaw in AI drug discovery, aiming to unlock a new generation of therapies.

The deal creates an end-to-end commercialization powerhouse, tackling pharma's toughest payer, reimbursement, and patient affordability challenges.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

A new patient app from BrightInsight and Sanofi reduced therapy discontinuation by 4%, proving digital tools can solve medicine's adherence problem.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

As Sotera Health prepares for the J.P. Morgan conference, strong financials clash with legal challenges, putting its mission-critical role under scrutiny.

Pharma giant Bayer partners with AI innovator Cradle, betting on generative AI to accelerate its biologics pipeline and reshape modern medicine.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.